X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs WYETH LTD - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA WYETH LTD SUN PHARMA/
WYETH LTD
 
P/E (TTM) x 26.1 27.7 94.3% View Chart
P/BV x 3.8 5.3 71.4% View Chart
Dividend Yield % 0.6 1.3 47.3%  

Financials

 SUN PHARMA   WYETH LTD
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
WYETH LTD
Mar-13
SUN PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs8421,044 80.6%   
Low Rs572818 70.0%   
Sales per share (Unadj.) Rs131.6298.6 44.1%  
Earnings per share (Unadj.) Rs32.757.2 57.1%  
Cash flow per share (Unadj.) Rs38.058.4 65.0%  
Dividends per share (Unadj.) Rs3.5017.00 20.6%  
Dividend yield (eoy) %0.51.8 27.1%  
Book value per share (Unadj.) Rs152.7249.5 61.2%  
Shares outstanding (eoy) m2,399.2622.72 10,560.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.43.1 172.3%   
Avg P/E ratio x21.616.3 132.9%  
P/CF ratio (eoy) x18.615.9 116.8%  
Price / Book Value ratio x4.63.7 124.1%  
Dividend payout %10.729.7 36.0%   
Avg Mkt Cap Rs m1,696,87721,157 8,020.5%   
No. of employees `00017.50.5 3,560.2%   
Total wages/salary Rs m49,023400 12,255.8%   
Avg. sales/employee Rs Th18,028.313,787.4 130.8%   
Avg. wages/employee Rs Th2,798.8813.0 344.2%   
Avg. net profit/employee Rs Th4,479.52,643.3 169.5%   
INCOME DATA
Net Sales Rs m315,7846,783 4,655.3%  
Other income Rs m6,232353 1,767.3%   
Total revenues Rs m322,0167,136 4,512.6%   
Gross profit Rs m100,8931,617 6,238.3%  
Depreciation Rs m12,64827 47,547.0%   
Interest Rs m3,9986 72,690.9%   
Profit before tax Rs m90,4791,938 4,669.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m12,116632 1,916.4%   
Profit after tax Rs m78,4621,301 6,033.2%  
Gross profit margin %31.923.8 134.0%  
Effective tax rate %13.432.6 41.0%   
Net profit margin %24.819.2 129.6%  
BALANCE SHEET DATA
Current assets Rs m329,5376,984 4,718.5%   
Current liabilities Rs m178,8702,056 8,700.3%   
Net working cap to sales %47.772.6 65.7%  
Current ratio x1.83.4 54.2%  
Inventory Days Days7999 79.6%  
Debtors Days Days8324 347.8%  
Net fixed assets Rs m204,766244 83,817.2%   
Share capital Rs m2,399227 1,056.0%   
"Free" reserves Rs m363,9975,441 6,690.1%   
Net worth Rs m366,3975,668 6,464.3%   
Long term debt Rs m14,36125 57,443.2%   
Total assets Rs m614,1027,901 7,772.5%  
Interest coverage x23.6353.3 6.7%   
Debt to equity ratio x00 888.6%  
Sales to assets ratio x0.50.9 59.9%   
Return on assets %13.416.5 81.2%  
Return on equity %21.422.9 93.3%  
Return on capital %24.834.0 73.0%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m44,11815 290,250.7%   
Fx outflow Rs m24,4842,677 914.5%   
Net fx Rs m19,634-2,662 -737.6%   
CASH FLOW
From Operations Rs m70,822923 7,671.4%  
From Investments Rs m-42,216317 -13,321.6%  
From Financial Activity Rs m-22,854-481 4,751.3%  
Net Cashflow Rs m6,107759 804.5%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 5.1 11.3 45.4%  
FIIs % 23.0 7.2 319.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 30.4 27.3%  
Shareholders   133,026 21,978 605.3%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  CIPLA  FDC LTD.  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jan 24, 2018 09:27 AM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - UNICHEM LAB COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS